| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/17/2000 | WO2000008191A2 Herpes virus vectors for dendritic cells |
| 02/17/2000 | WO2000008171A1 N-acetylglycosaminyl transferase genes |
| 02/17/2000 | WO2000008166A1 Recombinant poliovirus for the treatment of cancer |
| 02/17/2000 | WO2000008153A2 Arf-p19, a novel regulator of the mammalian cell cycle |
| 02/17/2000 | WO2000008150A1 Method for treatment of invasive cells |
| 02/17/2000 | WO2000008147A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | WO2000008145A2 Novel genes in control of hematopoiesis |
| 02/17/2000 | WO2000008144A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 02/17/2000 | WO2000008143A2 Gene isolated on the short arm of human chromosome 17 |
| 02/17/2000 | WO2000008141A2 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008140A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008139A1 Tumor necrosis factor-gamma |
| 02/17/2000 | WO2000008133A1 NOVEL G PROTEIN-COUPLED RECEPTOR cDNA SEQUENCE |
| 02/17/2000 | WO2000008053A1 Novel g-protein coupled receptor protein and dna thereof |
| 02/17/2000 | WO2000007630A1 Nucleic acid delivery |
| 02/17/2000 | WO2000007618A2 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 02/17/2000 | WO2000007577A2 Phosphatidylcholine as a medicament for the protection of mucosa |
| 02/17/2000 | WO2000007565A2 Methods of ophthalmic administration |
| 02/17/2000 | WO2000001815A3 Neurotrophic factors |
| 02/17/2000 | WO2000001720A3 Compositions and methods for treating papillomavirus-infected cells |
| 02/17/2000 | WO1999063101A3 Transfected cells and methods for treating diabetes |
| 02/17/2000 | WO1999062534B1 IL-6/sIL-6R COMPLEX FOR PROMOTION OF LIVER FUNCTIONS |
| 02/17/2000 | WO1999058691A3 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 02/17/2000 | WO1999056784A3 Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10 |
| 02/17/2000 | WO1999050461A9 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 02/17/2000 | WO1999049909A9 Revascularization apparatus having coaxial channeling and injecting means |
| 02/17/2000 | WO1999047180A9 Chimeric adenoviral vectors for targeted gene delivery |
| 02/17/2000 | WO1999046371A9 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 02/17/2000 | CA2346123A1 Recombinant poliovirus for the treatment of cancer |
| 02/17/2000 | CA2339416A1 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339413A1 Method for treatment of invasive cells |
| 02/17/2000 | CA2339352A1 N-acetylglycosaminyltransferase genes |
| 02/17/2000 | CA2339347A1 Novel g protein-coupled receptor cdna sequence |
| 02/17/2000 | CA2339340A1 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339322A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | CA2338385A1 Human receptor-associated proteins |
| 02/17/2000 | CA2338382A1 Herpesviral vectors for gene delivery |
| 02/17/2000 | CA2337963A1 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer |
| 02/17/2000 | CA2337904A1 Novel genes in control of hematopoiesis |
| 02/17/2000 | CA2336592A1 Cell lines for the propagation of mutated herpes viruses |
| 02/17/2000 | CA2335648A1 A novel g protein-coupled receptor protein and its dna |
| 02/16/2000 | EP0979870A1 Human Wnt-6 polypeptide |
| 02/16/2000 | EP0979869A1 Short oligonucleotides for the inhibition of VEGF expression |
| 02/16/2000 | EP0979311A1 $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES |
| 02/16/2000 | EP0979309A1 Oligonucleotides for enhanced bioavailability |
| 02/16/2000 | EP0979298A1 Metastasis models using green fluorescent protein (gfp) as a marker |
| 02/16/2000 | EP0979297A1 A conditional replication and expression system |
| 02/16/2000 | EP0979292A2 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
| 02/16/2000 | EP0979290A2 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| 02/16/2000 | EP0979106A1 Use of a modified baculovirus containing exogenous nucleic acid for the manufacture of a medicament for delivering said nucleic acid to the hepatocytes |
| 02/16/2000 | EP0979101A1 Recombinant canine adenovirus (cav) containing exogenous dna |
| 02/16/2000 | EP0979095A2 Use of conantokins for producing analgesia or for neuroprotection |
| 02/16/2000 | EP0979093A1 Arrestable therapeutic viral agent |
| 02/16/2000 | EP0979092A2 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 02/16/2000 | EP0979088A1 Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
| 02/16/2000 | CN1244870A Tissue specific expression of retinoblastoma protein |
| 02/16/2000 | CN1244807A Improved vacines |
| 02/16/2000 | CN1244803A Soluble CTLA4 mutant molecules and uses thereof |
| 02/15/2000 | US6025474 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
| 02/15/2000 | US6025341 Chimeric hepatitis B/hepatitis C virus vaccine |
| 02/15/2000 | US6025340 Surface expression of enzyme in gene directed prodrug therapy |
| 02/15/2000 | US6025339 Oligo is antisense to the initiation codon, the coding region or the 5' and 3' intronexon junctions of a gene encoding the adenosine a.sub.1 receptor or antisense to an adenosine a.sub.1 receptor mrna; and |
| 02/15/2000 | US6025337 Solid microparticles for gene delivery |
| 02/15/2000 | US6025198 Antisense modulation of Ship-2 expression |
| 02/15/2000 | US6025195 Liver-specific adenovirus expression vector |
| 02/15/2000 | US6025191 For diagnosis, immunotherapy, gene therapy and anticarcinogenic agents |
| 02/15/2000 | US6025180 Asp1 |
| 02/15/2000 | US6025156 Amino acid sequence; for discovery of antibiotics, bactericides, bacteristats against staphylococcus infections |
| 02/15/2000 | US6025155 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 02/15/2000 | US6025140 Membrane-permeable constructs for transport across a lipid membrane |
| 02/15/2000 | US6025130 Nucleotide sequence of gene; for screening of homozygotes, diagnosis, and prenatal screening using oligonucleotide primers |
| 02/15/2000 | US6025127 Diagnosing metastasis by analyzing tumor margin, chyle, blood or a local lymph node, having normal morphology; amplifying sample nucleic acids using specific oligonucleotides then detecting presence of nucleic acid; accurate staging |
| 02/15/2000 | US6024965 Immunology for treatment of aids and t-cell epitopes |
| 02/15/2000 | US6024961 Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
| 02/15/2000 | US6024688 Angiostatin fragments and method of use |
| 02/15/2000 | CA2006008C Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| 02/12/2000 | CA2248989A1 Novel compounds |
| 02/10/2000 | WO2000006775A1 Exon deletion antisense drug design and therapy |
| 02/10/2000 | WO2000006764A1 Gastrointestinal bacterial antibody factories |
| 02/10/2000 | WO2000006760A1 Use of constitutive transport elements for host range control |
| 02/10/2000 | WO2000006759A2 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| 02/10/2000 | WO2000006758A1 Self-deleting vectors for cancer therapy |
| 02/10/2000 | WO2000006743A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 02/10/2000 | WO2000006742A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 02/10/2000 | WO2000006740A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 02/10/2000 | WO2000006737A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 02/10/2000 | WO2000006736A2 Nucleic acids and proteins from group b streptococcus |
| 02/10/2000 | WO2000006734A1 Chondrogenic and osteogenic inducing molecule |
| 02/10/2000 | WO2000006729A1 Kdel receptor inhibitors |
| 02/10/2000 | WO2000006727A2 Human epidermal proteins hepi-1 to hepi-6 |
| 02/10/2000 | WO2000006725A1 Method for diagnosing hereditary diseases by using semaphorin w gene |
| 02/10/2000 | WO2000006723A1 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| 02/10/2000 | WO2000006720A1 A novel regulatory molecule and genetic sequences encoding same |
| 02/10/2000 | WO2000006716A1 Growth differentiation factor-11 |
| 02/10/2000 | WO2000006709A1 Human protein kinase h2lau20 |
| 02/10/2000 | WO2000006705A2 Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy |
| 02/10/2000 | WO2000006698A1 98 human secreted proteins |
| 02/10/2000 | WO2000006696A2 Method for the modulation of function of transcription factors |
| 02/10/2000 | WO2000006601A1 Isoforms of human calcium sensing receptor |
| 02/10/2000 | WO2000006600A1 Human mink gene mutations associated with arrhythmia |